Business Description
ISIN : US9224751084
Share Class Description:
VEEV: Class ATotal Employee Number:
7,928Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 70.95 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.1 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 15.6 | |||||
Beneish M-Score | -2.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13 | |||||
3-Year EBITDA Growth Rate | 23.9 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | 20.8 | |||||
3-Year Book Growth Rate | 23.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.61 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.53 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.27 | |||||
9-Day RSI | 68.94 | |||||
14-Day RSI | 69.67 | |||||
3-1 Month Momentum % | 19.57 | |||||
6-1 Month Momentum % | 4.95 | |||||
12-1 Month Momentum % | -32.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.74 | |||||
Quick Ratio | 4.74 | |||||
Cash Ratio | 4.3 | |||||
Days Sales Outstanding | 67.23 | |||||
Days Payable | 16.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 0.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.02 | |||||
Operating Margin % | 28.79 | |||||
Net Margin % | 28.37 | |||||
EBITDA Margin % | 29.99 | |||||
FCF Margin % | 50.17 | |||||
OCF Margin % | 50.17 | |||||
ROE % | 13.68 | |||||
ROA % | 11.22 | |||||
ROIC % | 31.44 | |||||
3-Year ROIIC % | 32.34 | |||||
ROC (Joel Greenblatt) % | 686.25 | |||||
ROCE % | 13.66 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 44.19 | |||||
Forward PE Ratio | 27.36 | |||||
PE Ratio without NRI | 29.76 | |||||
Shiller PE Ratio | 79.84 | |||||
PEG Ratio | 1.98 | |||||
PS Ratio | 12.44 | |||||
PB Ratio | 5.53 | |||||
Price-to-Tangible-Book | 5.97 | |||||
Price-to-Free-Cash-Flow | 24.78 | |||||
Price-to-Operating-Cash-Flow | 24.78 | |||||
EV-to-EBIT | 34.59 | |||||
EV-to-Forward-EBIT | 24.84 | |||||
EV-to-EBITDA | 33.21 | |||||
EV-to-Forward-EBITDA | 24.2 | |||||
EV-to-Revenue | 9.96 | |||||
EV-to-Forward-Revenue | 9.13 | |||||
EV-to-FCF | 19.85 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 1.9 | |||||
Price-to-DCF (Earnings Based) | 0.95 | |||||
Price-to-DCF (FCF Based) | 0.79 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.92 | |||||
Price-to-Graham-Number | 2.81 | |||||
| Price-to-Net-Current-Asset-Value | 6.48 | |||||
| Price-to-Net-Cash | 7.36 | |||||
Earnings Yield (Greenblatt) % | 2.89 | |||||
FCF Yield % | 4.14 | |||||
Forward Rate of Return (Yacktman) % | 18.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:VEEV
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Veeva Systems Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,319.216 | ||
| EPS (TTM) ($) | 5.61 | ||
| Beta | 0.401 | ||
| 3-Year Sharpe Ratio | 0.01 | ||
| 3-Year Sortino Ratio | 0.02 | ||
| Volatility % | 35.13 | ||
| 14-Day RSI | 69.67 | ||
| 14-Day ATR ($) | 8.375815 | ||
| 20-Day SMA ($) | 226.4245 | ||
| 12-1 Month Momentum % | -32.96 | ||
| 52-Week Range ($) | 148.05 - 310.5 | ||
| Shares Outstanding (Mil) | 162.44 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veeva Systems Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veeva Systems Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2026-11-20 17:00 | In 91 days | ||
| Third quarter earnings results for 2027 | 2026-11-20 | In 90 days | ||
| Second quarter earnings conference call for 2027 | 2026-08-26 17:00 | In 5 days | ||
| Second quarter earnings results for 2027 | 2026-08-26 | In 4 days | ||
| General meeting for 2026 | 2026-06-17 09:00 | 163.38 (+0.85%) | ||
| First quarter earnings conference call for 2027 | 2026-06-03 17:00 | 182.94 (-0.97%) | ||
| First quarter earnings results for 2027 | 2026-06-03 | 182.94 (-0.97%) | ||
| Annual report for 2026 | 2026-03-20 | 185.59 (+0.95%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-03-04 17:00 | 185.91 (+4.23%) | ||
| Fourth quarter earnings results for 2026 | 2026-03-04 | 185.91 (+4.23%) |
Veeva Systems Inc Frequently Asked Questions
Guru Commentaries on NYSE:VEEV
Veeva is the dominant vertical market software system of record for the life sciences industry. Their customers rely on and trust Veeva to help them run their entire business. Veeva grew revenue and EBIT 16% and 24%, respectively in 2025 and it is off to a strong start in 2026. We believe Veeva is one of the most resilient software businesses on our MVP list due to the mission critical nature of its platform and its focus on the highly regulated life sciences industry. Veeva continues to innovate, embedding industry specific, compliant AI into its deeply integrated core applications. We see AI as just another growth driver for Veeva and believe the company will lean on its core strengths including its proprietary data, domain expertise, integrated platform, and trusted, embedded customer relationships to win.
Veeva Systems is the dominant, mission-critical software provider to the life sciences industry, with over 1,500 customers, including 19 of the top 20 global pharmaceutical companies. As pharmaceutical companies navigate drug development, nearly every step occurs on a Veeva product, making it exceptionally difficult to displace. Veeva's decades of industry-specific data and domain specialization provide a durable moat. The company is well-positioned to leverage AI, as its governed data foundation is crucial in a regulated industry. Veeva's credibility advantage in compliance and audit requirements, combined with its ongoing AI developments, positions it favorably in the race for AI in life sciences.
Press Release
Articles on Veeva Systems Inc
Headlines
See More- 1
- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
